Growth
Pressure to exploit connected care functionality is accelerating the shift in care delivery away from the inpatient setting. Medtechs are reshaping to maximize faster-growth opportunities.
Nine biopharma companies made 12 or more deals, with Novartis inking 21 deals and leading M&A activity. Roche, meanwhile, spent little up front but maintained a hectic pace with 12 alliances.
As Eli Lilly and Novo Nordisk reap the blockbuster rewards of their rival obesity therapies the companies are also bulking up their organizations to make the most of the phenomenal rise of the GLP-1 class.
Despite experiencing significant drops in pharmaceutical revenues in 2023, Pfizer and AbbVie maintained their top positions, ranking first and second respectively, in the latest Scrip 100.
Pfizer continued its reign as the Scrip 100 leader for a third year, while Lilly and Novo climbed higher.
As the US biosimilars market approaches the end of its first decade, it has seen another busy year, with Amgen’s surprise launch of a rival to Eylea shaking up expectations as other first-time approvals rolled in throughout 2024. Meanwhile, competition to Stelara is waiting in the wings from the start of 2025.
Venture capital funding is up, and initial and follow-on public offerings are growing, but the building wave of investment in biopharma has not reached all companies.
GLP-1 drugs like Ozempic and Mounjaro have shaken up pharma, crossing firmly over into the mainstream while netting fortunate suppliers billions of dollars in the process. As patent expiry approaches for first- and second-generation products, generics manufacturers are gearing up to take a share of the spoils.
Ten $1bn+ alliances were penned in October, and three exceeded $2bn.
As the pharmaceutical industry readies itself to navigate the complexities of 2025, US pricing trends reveal a landscape shaped by regulatory and legislative changes, innovative pricing models, and the ongoing impact of inflation.
Despite the importance of developing and commercializing new products to fuel pharma revenue growth, it is estimated that approximately up to 50% of drug launches fail to meet financial expectations. We explore how to maximize product success in pharma's value era.
While Japanese firms still dominate the money spinners in Asia, companies from China and, lesser so, India are starting to stand out from the crowd.
Our latest ranking of the world’s leading off-patent companies reflects a fairly stable leading group this year – but this belies the significant evolutions seen for major generics and biosimilars players over the past 12 months.
Since taking on the CEO role at Theratechnologies in 2020, Paul Lévesque has made it his priority to beef up the company’s commercial portfolio and look for partnerships on potentially high-value programs. Now, the Canadian biotech is turning a profit for the first time in many years.
While big pharma has significantly higher R&D and acquisition expenditures, certain biotechs have outperformed in terms of ROI and have substantial potential for future growth with their strong pipeline assets.
Schrödinger has for years discovered drug candidates for other companies and derisked them, testing them in silico using its computational models. Now, it is exploring its own ability to develop drugs in the clinic, starting with low-risk bets. Will the company’s approach succeed where others have failed?
An interactive look at pharma, medtech and diagnostics deals made during August 2024. Data courtesy of Biomedtracker.
Dealmakers from CAR-T biotech Poseida Therapeutics and Astellas recently sat down with In Vivo to discuss how they reached a $600m deal that combines their technologies and how they plan on moving forward.